Evidence quality 4.75/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
● your factors — click this risk ▾ to reveal
- Your factors
≈ As likely as
Perceived
Parents consistently rank childhood cancer among their greatest fears, and the perceived probability sits well above the actual rate. The vividness and emotional weight of childhood cancer diagnoses in media coverage — charity drives, viral fundraising stories, celebrity disclosures — create an availability cascade that inflates intuitive estimates dramatically. When researchers ask parents to estimate the likelihood that their child will develop cancer before adulthood, the guesses routinely fall between 5% and 20%, far above the actual cumulative incidence of roughly 1 in 285. The gap is amplified by the severity of the outcome: even a very small probability feels large when the outcome is cancer in a child.
Rough estimate: Most parents would guess somewhere between 1 in 20 and 1 in 5 — roughly 14 to 57 times the actual rate
Source: editorial intuition, not polled
Actual
roughly 216 children diagnosed with cancer per 1,000,000 children per year (US, ages 0–19)
US children aged 0–19
Show derivation
NCI SEER data (2023 Cancer Statistics Review, Childhood Cancer Statistics table) reports approximately 15,780 new cancer cases per year among US children aged 0–19 (average 2016–2020). The US Census Bureau estimated approximately 73 million children under age 20 in that period. Annual incidence rate: 15,780 / 73,000,000 ≈ 216 per million (21.6 per 100,000) per year. Cumulative childhood probability (20 independent annual-trial approximation): P = 1 − (1 − 0.000216)^20 ≈ 0.00430. However, NCI's own published summary statistic "approximately 1 in 285 children will be diagnosed with cancer before age 20" is the authoritative figure (0.003509) — it incorporates age-specific rate variation more precisely than the simple constant-rate approximation. This entry uses 0.00351 as the point estimate, consistent with the NCI published summary. Scope: subgroup_lifetime — probability that a given child receives a cancer diagnosis during their 0–19 childhood, not a US adult's remaining lifetime probability.
Caveats: This entry covers all cancer types (malignant neoplasms) diagnosed before age 20…
This entry covers all cancer types (malignant neoplasms) diagnosed before age 20 in the US. The headline figure "1 in 285" is NCI's published cumulative incidence summary for the childhood period and is the most authoritative single-number characterization of this risk. It does not include benign brain tumors, which are separately tracked and roughly double the total intracranial tumor burden. The 5-year survival rate has improved dramatically from roughly 58% in the mid-1970s to approximately 85% today, meaning that a childhood cancer diagnosis is no longer synonymous with a fatal prognosis for most types. Survival rates vary substantially by cancer type: acute lymphoblastic leukemia (the most common type) now has a 5-year survival exceeding 90%, while diffuse intrinsic pontine glioma (DIPG) remains near-uniformly fatal. The personal factor multipliers for Down syndrome and Li-Fraumeni syndrome apply to very specific genetically defined populations and should not be extrapolated to general familial cancer history without genetic counseling. Racial/ethnic disparities exist in childhood cancer incidence (higher rates in White children for ALL; higher rates of certain tumors in other groups) and in survival outcomes.
Related risks
Other risks on similar themes — for exploring related fears.
Infant pool submersion
What are the odds of a pool submersion injury serious enough to need emergency care for a child under 4?
Unsafe imported products
What are the odds of being harmed by an unsafe imported consumer product?
Counterfeit medicine
What are the odds of being harmed or killed by a counterfeit or substandard medicine?
Pick challenger
Ward and colleagues’ 2014 analysis in CA: A Cancer Journal for Clinicians, drawing on National Cancer Institute SEER surveillance data, estimates that approximately 15,780 children and adolescents aged 0–19 are diagnosed with cancer each year in the United States — roughly 1 in 285 children before their twentieth birthday. That cumulative incidence figure works out to about 216 per million children per year across the full 0–19 window. Leukemias, brain and other central nervous system tumors, and lymphomas are the most common categories, in that order, followed by a heterogeneous set of solid tumors including neuroblastoma, Wilms tumor, bone tumors, and soft-tissue sarcomas. Most parents, if asked to estimate the probability, give numbers far higher — often between 1 in 20 and 1 in 5 — placing their intuitive guess roughly 15 to 50 times above the actual rate. The gap is not surprising: childhood cancer diagnoses, because they are genuinely rare and emotionally freighted, receive media and fundraising attention wildly disproportionate to their statistical frequency, distorting the availability heuristic that underpins intuitive risk perception.
The survival landscape has been transformed over the past five decades in a way that is itself poorly understood by the public. The overall 5-year survival rate for childhood cancers has risen from roughly 58% in the mid-1970s to approximately 85% today, driven by advances in chemotherapy protocols, targeted agents, immunotherapy, and supportive care. Acute lymphoblastic leukemia — the most common childhood cancer — now carries a 5-year survival exceeding 90% in high-income countries. A childhood cancer diagnosis is a serious and demanding medical experience, but it is no longer, in most cases, a death sentence. This matters for risk perception: parents’ mental model of childhood cancer is often anchored in historical outcomes or in the highest-severity cases that generate the most coverage, compounding the probabilistic overestimate with a severity overestimate. The realistic scenario — roughly 85% of diagnosed children surviving beyond five years — is underweighted in intuitive assessments.
Risk is not uniform across the childhood period or across population subgroups. Incidence peaks in children aged 1–4 (driven by the ALL peak), declines in middle childhood, and rises again in adolescence with lymphomas, bone tumors, and germ cell tumors. Boys carry roughly a 20% higher overall incidence than girls, reflecting male predominance in leukemia and lymphoma. Genetic factors shift individual risk markedly in specific cases: children with Down syndrome face a 10–20-fold elevated risk of leukemia; Li-Fraumeni syndrome families carry substantially elevated risks of sarcomas, brain tumors, and other malignancies in childhood and adolescence. Childhood cancer survivors who received radiation therapy face an approximately 3-fold elevated risk of a second primary malignancy later in life — a risk that is real but borne by a subset of an already-small population. For the overwhelming majority of children without such predisposing conditions, the population-average figure of roughly 1 in 285 is the appropriate planning baseline.
Related tidbits
Roughly 1 in 285 US children are diagnosed with cancer before age 20. Parents asked to estimate it routinely guess between 1 in 20 and 1 in 5, tens of times above the actual rate.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
1/2 sources independently verified verbatim against the cited source
-
[1] National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program — Cancer in Children and Adolescents — NCI Fact Sheet Verified
Cancer in Children and Adolescents — NCI Fact Sheet- Statistic
An estimated 14,910 children and adolescents aged 0–19 will be diagnosed with cancer in the US in 2024; 5-year relative survival ~83–88% across childhood age bands (2013–2019)- Excerpt
“"It is estimated that, in 2024, a total of 14,910 children and adolescents ages 0 to 19 will be diagnosed with cancer... In 2013–2019, 5-year survival was 83.2% for children younger than 1 year, 87.8% for children ages 1–4 years, 85.7% for children ages 5–9 years, 85.5% for children ages 10–14 years, and 87.3% for adolescents ages 15–19 years." ”
- Source data from
- 2024-08-01
- Accessed
- 2026-06-30 · archived copy
- Verification
- Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
- Calculation
- Authoritative government source for the annual case count and survival range. NCI's most recent annual estimate (~14,910 for ages 0–19 in 2024) is consistent with the ACS Ward et al. (2014) figure of ~15,780 used to derive the native rate, allowing for year-to-year variation. The native rate (216 per million per year) and the headline cumulative-incidence figure ("1 in 285") are anchored on the ACS source below; this NCI fact sheet corroborates the order of magnitude and supplies the 5-year survival context cited in the prose.
-
[2] Ward et al., CA: A Cancer Journal for Clinicians (American Cancer Society) — Childhood and adolescent cancer statistics, 2014
Childhood and adolescent cancer statistics, 2014- Statistic
An estimated 15,780 new cancer cases and 1,960 deaths among US children/adolescents aged 0–19 in 2014; ~1 in 285 children diagnosed before age 20; annual incidence 186.6 per 1 million (ages 0–19)- Excerpt
“"In 2014, an estimated 15,780 new cases of cancer will be diagnosed and 1960 deaths will occur among children and adolescents aged birth to 19 years... Approximately 1 in 285 children will be diagnosed with cancer before age 20 years. The annual incidence rate of cancer in children and adolescents is 186.6 per 1 million children aged birth to 19 years." ”
- Source data from
- 2014-01-31
- Accessed
- 2026-06-30 · archived copy
- Calculation
- Authoritative peer-reviewed origin of this entry's two headline figures: the ~15,780 annual case count for ages 0–19 and the "1 in 285" cumulative childhood-incidence summary. DOI 10.3322/caac.21219, PMID 24488779. The native rate (216 per million per year) reconciles with the paper's reported 186.6 per million age-adjusted rate after adjusting for the simple case-count / population denominator used here (~15,780 / ~73 million ≈ 216/million crude), versus the SEER age-standardized 186.6/million. The "1 in 285" figure (= 0.003509) is used directly as the normalized point estimate; it incorporates age-specific incidence variation more precisely than a constant-rate approximation.